{"transactions":[{"id":714858,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":714857,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":16000,"price":2.49,"value":39840.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":714856,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":1.03,"value":16480.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":715309,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:30:25.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":948,"price":54.2816,"value":51458.9568,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.040 to $54.795, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Consists of 107,818 shares of common stock and 6,839 RSUs."}],"balance_after":114657,"source":{"system":"sec-edgar","filing":"0001193125-26-296248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000119312526296248/ownership.xml","form_type":"4"}},{"id":715308,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:30:25.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":2105,"price":53.494,"value":112604.87,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.050 to $54.030, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Consists of 108,766 shares of common stock and 6,839 RSUs."}],"balance_after":115605,"source":{"system":"sec-edgar","filing":"0001193125-26-296248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000119312526296248/ownership.xml","form_type":"4"}},{"id":727902,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:18:45.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":1250000,"price":16,"value":20000000.0,"ownership":{"direct":false,"nature":"By: ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":15042035,"source":{"system":"sec-edgar","filing":"0001012975-26-000564","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000101297526000564/form4.xml","form_type":"4"}},{"id":730778,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":2306401,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3673635},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730777,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":1204000,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1917731},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730776,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":5148587,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8200669},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730775,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":13792035,"ownership":{"direct":false,"nature":"By: ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":13792035,"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":746225,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:52:52.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":4310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date."}],"balance_after":4310,"derivative":{"exercise_price":45.33,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":4310},"source":{"system":"sec-edgar","filing":"0001104659-26-071428","document":"tm2617049-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926071428/tm2617049-4_4seq1.xml","form_type":"4"}},{"id":746224,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:52:52.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":6839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 110,871 shares of common stock and 6,839 RSUs."}],"balance_after":117710,"source":{"system":"sec-edgar","filing":"0001104659-26-071428","document":"tm2617049-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926071428/tm2617049-4_4seq1.xml","form_type":"4"}},{"id":758924,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T20:34:10.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026."}],"balance_after":80000,"derivative":{"exercise_price":1.86,"expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001610717-26-000174","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000174/form4.xml","form_type":"4"}},{"id":794166,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2681265,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2681265},"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794165,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2513686,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2513686},"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794164,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"purchase","planned":false,"acquired":true,"shares":1100000,"price":18,"value":19800000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6294951,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794163,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":2681265,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":5194951,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794162,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":2513686,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2513686,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":800980,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-24T20:05:11.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This stock option vested on May 22, 2025. No shares remain unvested under this stock option."}],"balance_after":0,"derivative":{"exercise_price":8.36,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-26-048551","document":"tm2612694-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926048551/tm2612694-1_4seq1.xml","form_type":"4"}},{"id":800979,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-24T20:05:11.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":false,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This stock option vested on June 21, 2024. No shares remain unvested under this stock option."}],"balance_after":0,"derivative":{"exercise_price":9.11,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001104659-26-048551","document":"tm2612694-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926048551/tm2612694-1_4seq1.xml","form_type":"4"}},{"id":800978,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-24T20:05:11.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This stock option vested on May 26, 2023. No shares remain unvested under this stock option."}],"balance_after":0,"derivative":{"exercise_price":4.75,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-26-048551","document":"tm2612694-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926048551/tm2612694-1_4seq1.xml","form_type":"4"}},{"id":800977,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-24T20:05:11.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":false,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This stock option vested on May 26, 2022. No shares remain unvested under this stock option."}],"balance_after":0,"derivative":{"exercise_price":26.78,"expiration_date":"2031-05-27","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001104659-26-048551","document":"tm2612694-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926048551/tm2612694-1_4seq1.xml","form_type":"4"}},{"id":800976,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-24T20:05:11.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":true,"shares":18000,"price":8.36,"value":150480.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Consists of 103,239 shares of common stock and 7,632 RSUs."}],"balance_after":110871,"source":{"system":"sec-edgar","filing":"0001104659-26-048551","document":"tm2612694-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926048551/tm2612694-1_4seq1.xml","form_type":"4"}},{"id":800975,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-24T20:05:11.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":true,"shares":36000,"price":9.11,"value":327960.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Consists of 85,239 shares of common stock and 7,632 RSUs."}],"balance_after":92871,"source":{"system":"sec-edgar","filing":"0001104659-26-048551","document":"tm2612694-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926048551/tm2612694-1_4seq1.xml","form_type":"4"}},{"id":800974,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-24T20:05:11.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":true,"shares":28000,"price":4.75,"value":133000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 49,239 shares of common stock and 7,632 RSUs.."}],"balance_after":56871,"source":{"system":"sec-edgar","filing":"0001104659-26-048551","document":"tm2612694-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926048551/tm2612694-1_4seq1.xml","form_type":"4"}},{"id":800973,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-24T20:05:11.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":true,"shares":7800,"price":26.78,"value":208884.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of 21,239 shares of common stock and 7,632 RSUs."}],"balance_after":28871,"source":{"system":"sec-edgar","filing":"0001104659-26-048551","document":"tm2612694-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926048551/tm2612694-1_4seq1.xml","form_type":"4"}},{"id":853893,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":1,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":3,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20890,"kind":"person","name":"BERNS PAUL L","position":8,"cik":"0001202769","reported_name":"BERNS PAUL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":9,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-09T20:34:54.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":488090,"price":25.61,"value":12499984.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP.  Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1426528,"source":{"system":"sec-edgar","filing":"0001012975-26-000234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000101297526000234/form4.xml","form_type":"4"}},{"id":1000558,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-13T21:10:04.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":148953,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,"},{"field":"security","element":"securityTitle","label":"F4","text":"(Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option provided for vesting in 36 substantially equal monthly installments from November 12, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.18,"expiration_date":"2034-11-11","underlying":"Common Stock","underlying_shares":148953},"source":{"system":"sec-edgar","filing":"0001193125-25-280808","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280808/ownership.xml","form_type":"4"}},{"id":1000557,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-13T21:10:04.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16125,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,"},{"field":"security","element":"securityTitle","label":"F4","text":"(Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025."}],"balance_after":0,"derivative":{"exercise_price":29.25,"expiration_date":"2035-05-19","underlying":"Common Stock","underlying_shares":16125},"source":{"system":"sec-edgar","filing":"0001193125-25-280808","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280808/ownership.xml","form_type":"4"}},{"id":1000556,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-11-13T21:10:04.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":2688,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On November 12, 2025, the Reporting Person was granted restricted stock units (\"RSUs\") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock.  The RSUs vest in 36 substantially equal monthly installments from November 12, 2025.  Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU.  There is no vesting applicable to the cash payment and the CVRs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On November 12, 2025, the Reporting Person was granted restricted stock units (\"RSUs\") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock.  The RSUs vest in 36 substantially equal monthly installments from November 12, 2025.  Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU.  There is no vesting applicable to the cash payment and the CVRs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On November 12, 2025, the Reporting Person was granted restricted stock units (\"RSUs\") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock.  The RSUs vest in 36 substantially equal monthly installments from November 12, 2025.  Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU.  There is no vesting applicable to the cash payment and the CVRs."}],"balance_after":2688,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2688},"source":{"system":"sec-edgar","filing":"0001193125-25-280808","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280808/ownership.xml","form_type":"4"}},{"id":1000555,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T21:10:04.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8313680,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-280808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280808/ownership.xml","form_type":"4"}},{"id":1000554,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T21:10:04.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7523682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-280808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280808/ownership.xml","form_type":"4"}},{"id":1000553,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T21:10:04.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18503128,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares of Common Stock held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares. Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-280808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280808/ownership.xml","form_type":"4"}},{"id":1000552,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T21:10:04.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17070904,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares of Common Stock held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares. Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-280808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280808/ownership.xml","form_type":"4"}},{"id":1000551,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T21:10:04.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On November 12, 2025, the Reporting Person was granted restricted stock units (\"RSUs\") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock.  The RSUs vest in 36 substantially equal monthly installments from November 12, 2025.  Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU.  There is no vesting applicable to the cash payment and the CVRs."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-280808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280808/ownership.xml","form_type":"4"}},{"id":1012115,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:22:24.000Z","date":"2025-10-27","kind":"purchase","planned":false,"acquired":true,"shares":1915700,"price":2.61,"value":4999977.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6046907,"source":{"system":"sec-edgar","filing":"0001012975-25-000681","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000101297525000681/form4.xml","form_type":"4"}},{"id":1077712,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73810,"kind":"organization","name":"ARCH Venture Partners X, L.P.","position":2,"cik":"0001782583","reported_name":"ARCH Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32126,"kind":"organization","name":"ARCH Venture Partners X Overage, L.P.","position":3,"cik":"0001768905","reported_name":"ARCH Venture Partners X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73809,"kind":"organization","name":"ARCH Venture Fund X, L.P.","position":4,"cik":"0001757011","reported_name":"ARCH Venture Fund X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32123,"kind":"organization","name":"ARCH Venture Fund X Overage, L.P.","position":5,"cik":"0001757017","reported_name":"ARCH Venture Fund X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":6,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":7,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-01T23:18:42.000Z","date":"2025-08-01","kind":"purchase","planned":false,"acquired":true,"shares":3030300,"price":3.3,"value":9999990.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6230300,"source":{"system":"sec-edgar","filing":"0001062993-25-013460","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000106299325013460/form4.xml","form_type":"4"}},{"id":1103490,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-23T21:11:29.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-089072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017025089072/ownership.xml","form_type":"4"}},{"id":1129457,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:50.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025."}],"balance_after":80000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-079923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079923/ownership.xml","form_type":"4"}},{"id":1129456,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:50.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":0.72,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-079923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079923/ownership.xml","form_type":"4"}},{"id":1129455,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:50.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":46455,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":46455,"derivative":{"exercise_price":0.72,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0000950170-25-079923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079923/ownership.xml","form_type":"4"}},{"id":1129454,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:50.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-079923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079923/ownership.xml","form_type":"4"}},{"id":1129453,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:50.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46455,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0000950170-25-079923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079923/ownership.xml","form_type":"4"}},{"id":1129303,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T20:31:54.000Z","date":"2025-05-29","kind":"sale","planned":true,"acquired":false,"shares":4400,"price":29.8338,"value":131268.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025 to cover tax withholding obligations upon the vesting and settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.59 to $30.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Consists of 13,439 shares of common stock and 7,632 RSUs."}],"balance_after":21071,"source":{"system":"sec-edgar","filing":"0001415889-25-015005","document":"form4-05302025_040512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000141588925015005/form4-05302025_040512.xml","form_type":"4"}},{"id":1129302,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T20:31:54.000Z","date":"2025-05-29","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":29.2419,"value":29241.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025 to cover tax withholding obligations upon the vesting and settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.57 to $29.49, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Consists of 17,839 shares of common stock and 7,632 RSUs."}],"balance_after":25471,"source":{"system":"sec-edgar","filing":"0001415889-25-015005","document":"form4-05302025_040512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000141588925015005/form4-05302025_040512.xml","form_type":"4"}},{"id":1135418,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:45:12.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":9206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date."}],"balance_after":9206,"derivative":{"exercise_price":30.46,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":9206},"source":{"system":"sec-edgar","filing":"0001104659-25-052479","document":"tm2516084-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925052479/tm2516084-5_4seq1.xml","form_type":"4"}},{"id":1135417,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:45:12.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":7632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2026 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 18,839 shares of Common Stock and 7,632 RSUs."}],"balance_after":26471,"source":{"system":"sec-edgar","filing":"0001104659-25-052479","document":"tm2516084-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925052479/tm2516084-5_4seq1.xml","form_type":"4"}},{"id":1137600,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T19:39:32.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":16125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable in 12 substantially equal monthly installments after the date of grant, such that the option will be vested in full on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":16125,"derivative":{"exercise_price":29.25,"expiration_date":"2035-05-19","underlying":"Common Stock","underlying_shares":16125},"source":{"system":"sec-edgar","filing":"0000950170-25-076578","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025076578/ownership.xml","form_type":"4"}},{"id":1264094,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:05.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":1.69,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-022317","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022317/ownership.xml","form_type":"4"}},{"id":1264093,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:05.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":46455,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":46455,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0000950170-25-022317","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022317/ownership.xml","form_type":"4"}},{"id":1264092,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:05.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":9.95,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-022317","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022317/ownership.xml","form_type":"4"}},{"id":1264091,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:05.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46455,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":46455},"source":{"system":"sec-edgar","filing":"0000950170-25-022317","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022317/ownership.xml","form_type":"4"}},{"id":1287666,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":2678571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\").  ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares.  Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1139951},"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1287665,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\").  ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares.  Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6383731},"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1287664,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":2678571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1139951},"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1287663,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6383730},"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1287662,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":19933333,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8483268},"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1287661,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"purchase","planned":false,"acquired":true,"shares":789998,"price":18,"value":14219964.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\").  ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares.  Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":8313680,"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1287660,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":7523682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\").  ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares.  Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":7523682,"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1287659,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"purchase","planned":false,"acquired":true,"shares":1432224,"price":18,"value":25780032.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":18503128,"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1287658,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:15:35.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":16006949,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":17070904,"source":{"system":"sec-edgar","filing":"0000950170-25-012590","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012590/ownership.xml","form_type":"4"}},{"id":1465850,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T22:19:53.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date."}],"balance_after":18000,"derivative":{"exercise_price":8.36,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001415889-24-018659","document":"form4-07012024_100750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000141588924018659/form4-07012024_100750.xml","form_type":"4"}},{"id":1465849,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-01T22:19:53.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest  on the earlier of June 15, 2025 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 5,339 shares of common stock and 13,500 RSUs."}],"balance_after":18839,"source":{"system":"sec-edgar","filing":"0001415889-24-018659","document":"form4-07012024_100750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000141588924018659/form4-07012024_100750.xml","form_type":"4"}},{"id":1479372,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:11:06.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":28571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":9.95,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0001610717-24-000334","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000334/form4.xml","form_type":"4"}},{"id":1479371,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-14T20:11:06.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":47717,"source":{"system":"sec-edgar","filing":"0001610717-24-000334","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000334/form4.xml","form_type":"4"}},{"id":1485283,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":11924138,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1392738},"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1485282,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":20000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2336000},"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1485281,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":3728738,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3728738,"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1547590,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":366301,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the \"AVP X Committee Members\"). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members other than the Reprting Person have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The Reporting Person is also an AVP X Committee Member and may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage.  The Reporting Person disclaims beneficial ownership of such shares except to any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by her for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":366301},"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547589,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":201465,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP.  Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC (\"AVP IX MDs\"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":201465},"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547588,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":164835,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP.  Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC (\"AVP IX MDs\"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":164835},"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547587,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":227920,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the \"AVP X Committee Members\"). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members other than the Reprting Person have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The Reporting Person is also an AVP X Committee Member and may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage.  The Reporting Person disclaims beneficial ownership of such shares except to any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by her for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":227920},"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547586,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":454212,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the \"AVP X Committee Members\"). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members other than the Reprting Person have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The Reporting Person is also an AVP X Committee Member and may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage.  The Reporting Person disclaims beneficial ownership of such shares except to any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by her for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":454212},"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547585,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":586080,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP.  Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC (\"AVP IX MDs\"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":586080},"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547584,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":424908,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP.  Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC (\"AVP IX MDs\"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":424908},"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547583,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"purchase","planned":false,"acquired":true,"shares":133333,"price":16,"value":2133328.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the \"AVP X Committee Members\"). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members other than the Reprting Person have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The Reporting Person is also an AVP X Committee Member and may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage.  The Reporting Person disclaims beneficial ownership of such shares except to any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by her for Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering."}],"balance_after":1181766,"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547582,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"purchase","planned":false,"acquired":true,"shares":66667,"price":16,"value":1066672.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP.  Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC (\"AVP IX MDs\"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Reflects shares purchased by ARCH IX in the Issuer's initial public offering."}],"balance_after":683759,"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547581,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":1048433,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the \"AVP X Committee Members\"). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members other than the Reprting Person have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The Reporting Person is also an AVP X Committee Member and may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage.  The Reporting Person disclaims beneficial ownership of such shares except to any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by her for Section 16 or any other purpose."}],"balance_after":1048433,"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547580,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":787545,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP.  Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC (\"AVP IX MDs\"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein."}],"balance_after":828570,"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1547579,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:49.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":589743,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP.  Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC (\"AVP IX MDs\"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein."}],"balance_after":617092,"source":{"system":"sec-edgar","filing":"0000950170-24-041844","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024041844/ownership.xml","form_type":"4"}},{"id":1557441,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2024-03-29T20:30:31.000Z","date":"2024-03-27","kind":"grant","planned":false,"acquired":true,"shares":26438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 36 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":26438,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":26438},"source":{"system":"sec-edgar","filing":"0000950170-24-038697","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569248/000095017024038697/ownership.xml","form_type":"4"}},{"id":1634284,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73810,"kind":"organization","name":"ARCH Venture Partners X, L.P.","position":2,"cik":"0001782583","reported_name":"ARCH Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32126,"kind":"organization","name":"ARCH Venture Partners X Overage, L.P.","position":3,"cik":"0001768905","reported_name":"ARCH Venture Partners X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73809,"kind":"organization","name":"ARCH Venture Fund X, L.P.","position":4,"cik":"0001757011","reported_name":"ARCH Venture Fund X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32123,"kind":"organization","name":"ARCH Venture Fund X Overage, L.P.","position":5,"cik":"0001757017","reported_name":"ARCH Venture Fund X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":6,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":7,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-20T22:37:44.000Z","date":"2024-02-15","kind":"purchase","planned":false,"acquired":true,"shares":3200000,"price":6.25,"value":20000000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3200000,"source":{"system":"sec-edgar","filing":"0001062993-24-003738","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000106299324003738/form4.xml","form_type":"4"}},{"id":1648965,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":3,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:43:56.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":727272,"price":5.5,"value":3999996.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":12446022,"source":{"system":"sec-edgar","filing":"0001062993-24-002841","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000106299324002841/form4.xml","form_type":"4"}},{"id":1648964,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":3,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:43:56.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":727272,"price":5.5,"value":3999996.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X).  ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":12446022,"source":{"system":"sec-edgar","filing":"0001062993-24-002841","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000106299324002841/form4.xml","form_type":"4"}},{"id":1648963,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":3,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:43:56.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":363637,"price":5.5,"value":2000003.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein."}],"balance_after":10667387,"source":{"system":"sec-edgar","filing":"0001062993-24-002841","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000106299324002841/form4.xml","form_type":"4"}},{"id":1700102,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-26T22:36:21.000Z","date":"2023-12-21","kind":"other","planned":false,"acquired":true,"shares":5339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of Common Stock held by a limited partnership to its partners for no consideration."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person."}],"balance_after":5339,"source":{"system":"sec-edgar","filing":"0001062993-23-023195","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000106299323023195/form4.xml","form_type":"4"}},{"id":1700101,"issuer":{"id":3721,"kind":"organization","name":"Scholar Rock Holding Corp","symbol":"SRRK"},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-26T22:36:21.000Z","date":"2023-12-21","kind":"other","planned":false,"acquired":false,"shares":291906,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of Common Stock held by a limited partnership to its partners for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by ARCH Venture Fund VIII, L.P. (\"ARCH VIII\"). ARCH Venture Partners VIII, L.P. (\"GPLP\"), as the sole general partner of ARCH VIII, may be deemed to beneficially own the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC (\"GPLLC\"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The GPLP and GPLLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The managing directors of the GPLLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH VIII.  Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.  The Reporting Person is a managing director of the GPLP.  The Reporting Person owns an interest in the GPLP but does not have voting or investment control over the shares held by ARCH VIII. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein."}],"balance_after":2345711,"source":{"system":"sec-edgar","filing":"0001062993-23-023195","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727196/000106299323023195/form4.xml","form_type":"4"}},{"id":1714597,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:52:03.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":13997,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones.  Shares were received without any action by the Reporting Person.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones.  Shares were received without any action by the Reporting Person.  No additional consideration was paid for the shares."}],"balance_after":27617,"source":{"system":"sec-edgar","filing":"0001062993-23-022479","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022479/form4.xml","form_type":"4"}},{"id":1714596,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:52:03.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":1176593,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones.  Shares were received without any action by the Reporting Person.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones.  Shares were received without any action by the Reporting Person.  No additional consideration was paid for the shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":4131207,"source":{"system":"sec-edgar","filing":"0001062993-23-022479","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022479/form4.xml","form_type":"4"}},{"id":1714595,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:52:03.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":703061,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones.  Shares were received without any action by the Reporting Person.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones.  Shares were received without any action by the Reporting Person.  No additional consideration was paid for the shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1387228,"source":{"system":"sec-edgar","filing":"0001062993-23-022479","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022479/form4.xml","form_type":"4"}},{"id":1740988,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T23:55:01.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":3357,"price":11.98,"value":40216.86,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.89 to $12.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":4131207,"source":{"system":"sec-edgar","filing":"0001062993-23-020934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020934/form4.xml","form_type":"4"}},{"id":1740987,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T23:55:01.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":31653,"price":11.75,"value":371922.75,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.52 to $12.00, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":4127850,"source":{"system":"sec-edgar","filing":"0001062993-23-020934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020934/form4.xml","form_type":"4"}},{"id":1744263,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:01:41.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":5431,"price":11.75,"value":63814.25,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.63 to $11.8922, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":4096197,"source":{"system":"sec-edgar","filing":"0001062993-23-020714","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020714/form4.xml","form_type":"4"}},{"id":1744262,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:01:41.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":11844,"price":11.37,"value":134666.28,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.62 to $11.61, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":4090766,"source":{"system":"sec-edgar","filing":"0001062993-23-020714","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020714/form4.xml","form_type":"4"}},{"id":1744261,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:01:41.000Z","date":"2023-11-09","kind":"purchase","planned":false,"acquired":true,"shares":31079,"price":10.53,"value":327261.87,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.445 to $10.7975, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":4078922,"source":{"system":"sec-edgar","filing":"0001062993-23-020714","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020714/form4.xml","form_type":"4"}},{"id":1744260,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:01:41.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":23124,"price":11.79,"value":272631.96,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.5007 to $12.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":4047843,"source":{"system":"sec-edgar","filing":"0001062993-23-020714","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020714/form4.xml","form_type":"4"}},{"id":1744259,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:01:41.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":69127,"price":10.78,"value":745189.06,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.4891, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":4024719,"source":{"system":"sec-edgar","filing":"0001062993-23-020714","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020714/form4.xml","form_type":"4"}},{"id":1747756,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-08T00:00:44.000Z","date":"2023-11-07","kind":"purchase","planned":false,"acquired":true,"shares":30192,"price":11.5,"value":347208.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.67, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":3955592,"source":{"system":"sec-edgar","filing":"0001062993-23-020280","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020280/form4.xml","form_type":"4"}},{"id":1747755,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-08T00:00:44.000Z","date":"2023-11-06","kind":"purchase","planned":false,"acquired":true,"shares":43082,"price":11.55,"value":497597.1,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.99, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":3925400,"source":{"system":"sec-edgar","filing":"0001062993-23-020280","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020280/form4.xml","form_type":"4"}},{"id":1747754,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32075,"kind":"person","name":"Burow Kristina","position":1,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-08T00:00:44.000Z","date":"2023-11-03","kind":"purchase","planned":false,"acquired":true,"shares":22420,"price":11.38,"value":255139.6,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.08 to $11.82, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023."}],"balance_after":3882318,"source":{"system":"sec-edgar","filing":"0001062993-23-020280","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020280/form4.xml","form_type":"4"}}],"next_cursor":"2023-11-08T00:00:44.000000Z,1747754"}